Carregant...
Targets of opportunity for precision medicine
In this issue of Blood, Schinke et al have identified a higher expression of CXCR2 in myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) stem cells than in normal hematopoietic stem cells (HSCs) and demonstrated preclinical therapeutic proof of principle.(1)
Guardat en:
| Publicat a: | Blood |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4432001/ https://ncbi.nlm.nih.gov/pubmed/25977578 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-04-638270 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|